nach oben

International Urology and Nephrology

Erschienen in:

01.02.2012 | Urology – Original Paper

Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma

verfasst von: Ying-Li Lin, Xiao-Qiang Liu, Wen-Ping Li, Guang Sun, Chun-Ting Zhang

Erschienen in: International Urology and Nephrology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Objectives

H-cadherin, functions as a tumor suppressor, is frequently silenced by promoter methylation in human cancers. The aim of this study was to evaluate the feasibility of using H-cadherin methylation in tumor tissues as a potential biomarker in patients with bladder transitional cell carcinoma (TCC).

Materials and methods

We examined the methylation status of H-cadherin in 133 primary bladder TCC samples and 43 normal bladder epithelial tissues using methylation-specific polymerase chain reaction (MSP) and then analyzed the associations between H-cadherin methylation and clinicopathologic features as well as patients’ outcome.

Results

H-cadherin methylation was detected in 47 (35.3%) bladder TCC samples, but not found in controls (P = 0.0000). Moreover, H-cadherin methylation was significantly associated with advanced stage (P = 0.0006), high grade (P = 0.0165), larger tumor size (P = 0.0225), tumor recurrence (P = 0.0106), and poor prognosis (P = 0.0000). In addition, multivariate analysis indicated that H-cadherin methylation is independently associated with poor outcome and had a relative risk of death of 3.832 (P = 0.0071, 95% confidence interval: 1.443–10.176).

Conclusions

The results suggest that H-cadherin methylation may be used as a potential biomarker for the malignancy of bladder TCC and as an independent prognostic biomarker in patients with bladder TCC.

Van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56:430–442PubMedCrossRef

Ploeg M, Aben KK, Kiemeney LA (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27:289–293PubMedCrossRef

Jacobs BL, Lee CT, Montie JE (2010) Bladder cancer in 2010: how far have we come? CA Cancer J Clin 60:244–272PubMedCrossRef

Rübben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G (1988) Natural history and treatment of low and high risk superficial bladder tumors. J Urol 139:283–285PubMed

Black PC, Dinney CP (2007) Bladder cancer angiogenesis and metastasis–translation from murine model to clinical trial. Cancer Metastasis Rev 26:623–634PubMedCrossRef

Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP (2006) Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 176:2414–2422PubMedCrossRef

Herr HW, Dotan Z, Donat SM, Bajorin DF (2007) Defining optimal therapy for muscle invasive bladder cancer. J Urol 177:437–443PubMedCrossRef

Morgan TM, Clark PE (2010) Bladder cancer. Curr Opin Oncol 22:242–249PubMedCrossRef

Andreeva AV, Kutuzov MA (2010) Cadherin 13 in cancer. Genes Chromosomes Cancer 49:775–790PubMed

10.

Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B, Ito T, Hamilton JP, David S, Agarwal R, Selaru FM, Sato F, Abraham JM, Beer DG, Mori Y, Shimada Y, Meltzer SJ (2008) Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int J Cancer 123:2331–2336PubMedCrossRef

11.

Kim DS, Kim MJ, Lee JY, Kim YZ, Kim EJ, Park JY (2007) Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Cancer 110:2785–2792PubMedCrossRef

12.

Dehan P, Kustermans G, Guenin S, Horion J, Boniver J, Delvenne P (2009) DNA methylation and cancer diagnosis: new methods and applications. Expert Rev Mol Diagn 9:651–657PubMedCrossRef

13.

Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225–3229PubMed

14.

Kim YK, Kim WJ (2009) Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol 16:17–22PubMedCrossRef

15.

Enokida H, Nakagawa M (2008) Epigenetics in bladder cancer. Int J Clin Oncol 13:298–307PubMedCrossRef

16.

Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zöchbauer-Müller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF (2001) Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 61:8659–8663PubMed

17.

Yu J, Zhu T, Wang Z, Zhang H, Qian Z, Xu H, Gao B, Wang W, Gu L, Meng J, Wang J, Feng X, Li Y, Yao X, Zhu J (2007) A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res 13:7296–7304PubMedCrossRef

18.

Oosterlinck W, Lobel B, Jakse G, Malmström PU, Stöckle M, Sternberg C (2002) Guidelines on bladder cancer. Eur Urol 41:105–112PubMedCrossRef

19.

Qian ZR, Sano T, Yoshimoto K, Asa SL, Yamada S, Mizusawa N, Kudo E (2007) Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol 20:1269–1277PubMedCrossRef

20.

Kim JS, Han J, Shim YM, Park J, Kim DH (2005) Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma. Cancer 104:1825–1833PubMedCrossRef

21.

Sakai M, Hibi K, Koshikawa K, Inoue S, Takeda S, Kaneko T, Nakao A (2004) Frequent promoter methylation and gene silencing of CDH13 in pancreatic cancer. Cancer Sci 95:588–591PubMedCrossRef

22.

Hibi K, Kodera Y, Ito K, Akiyama S, Nakao A (2004) Methylation pattern of CDH13 gene in digestive tract cancers. Br J Cancer 91:1139–1142PubMed

23.

Widschwendter A, Ivarsson L, Blassnig A, Müller HM, Fiegl H, Wiedemair A, Müller-Holzner E, Goebel G, Marth C, Widschwendter M (2004) CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer 109:163–166PubMedCrossRef

24.

Kim WJ, Kim YJ (2009) Epigenetic biomarkers in urothelial bladder cancer. Expert Rev Mol Diagn 9:259–269PubMedCrossRef

25.

Jung S, Jeong D, Kim J, Yi L, Koo K, Lee J, Lee SD, Park JW, Chang B, Kim CH, Kim CJ, Lee MS (2010) The role of hLHX6-HMR as a methylation biomarker for early diagnosis of cervical cancer. Oncol Rep 23:1675–1682PubMedCrossRef

26.

Huang YW, Jansen RA, Fabbri E, Potter D, Liyanarachchi S, Chan MW, Liu JC, Crijns AP, Brown R, Nephew KP, van der Zee AG, Cohn DE, Yan PS, Huang TH, Lin HJ (2009) Identification of candidate epigenetic biomarkers for ovarian cancer detection. Oncol Rep 22:853–861PubMedCrossRef

27.

Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet 374:239–249PubMedCrossRef

28.

Lopez-Beltran A (2008) Bladder cancer: clinical and pathological profile. Scand J Urol Nephrol Suppl 218:95–109PubMedCrossRef

29.

Yan Q, Zhang ZF, Chen XP, Gutmann DH, Xiong M, Xiao ZY, Huang ZY (2008) Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma. Int J Oncol 32:1057–1063PubMed

30.

Alumkal JJ, Zhang Z, Humphreys EB, Bennett C, Mangold LA, Carducci MA, Partin AW, Garrett-Mayer E, DeMarzo AM, Herman JG (2008) Effect of DNA methylation on identification of aggressive prostate cancer. Urology 72:1234–1239PubMedCrossRef

31.

Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG (2008) DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358:1118–1128PubMedCrossRef

32.

Parkin DM (2008) The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 218:12–20PubMedCrossRef

33.

Rouprêt M, Hupertan V, Yates DR, Comperat E, Catto JW, Meuth M, Lackmichi A, Ricci S, Lacave R, Gattegno B, Richard F, Hamdy FC, Cussenot O (2008) A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU Int 101:1448–1453PubMedCrossRef

Titel: Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma
verfasst von: Ying-Li Lin
Xiao-Qiang Liu
Wen-Ping Li
Guang Sun
Chun-Ting Zhang
Publikationsdatum: 01.02.2012
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 1/2012
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-011-9961-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objectives

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Ambulatory blood pressure monitoring: from old concepts to novel insights

Impact of newer unidirectional and bidirectional barbed suture on vesicourethral anastomosis during robot-assisted radical prostatectomy and its comparison with polyglecaprone-25 suture: an initial experience

Predictors for spontaneous stone passage in patients with renal colic secondary to ureteral calculi

Change in Editorship

Factors associated with diabetic nephropathy in subjects with proliferative retinopathy